L. van Doorn

发表

Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.

T. Visser, R. Peeters, R. Mathijssen, 2011, Thyroid : official journal of the American Thyroid Association.

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

J. Verweij, E. de Vries, J. Gietema, 2007, British Journal of Cancer.

Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy

E. Wiemer, J. Verweij, B. van der Holt, 2012, Clinical Cancer Research.

A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.

M. Cotreau, E. D. de Vries, A. Strahs, 2015, Clinical colorectal cancer.

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

M. Cotreau, J. Verweij, M. Thomeer, 2011, Clinical Cancer Research.

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib

S. Baker, A. Gibson, A. Sparreboom, 2020, Pharmaceutics.

Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.

R. Mathijssen, R. V. van Schaik, S. Bins, 2016, Pharmacogenomics.

Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer

R. Mathijssen, P. de Bruijn, M. Doukas, 2021, Frontiers in Pharmacology.

Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial

I. B. Borel Rinkes, C. Punt, M. D'Angelica, 2019, BMC Cancer.

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

J. Schellens, J. Beijnen, R. Mathijssen, 2016, Clinical Cancer Research.

An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors.

J. Verweij, H. Burger, K. Hayashi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine and the Risk of Fingerprint Loss

R. Mathijssen, S. Bins, L. Binkhorst, 2017, JAMA oncology.

The added value of H2 antagonists in premedication regimens during paclitaxel treatment

A. Jager, R. Mathijssen, I. Boere, 2021, British Journal of Cancer.

Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension

J. Versmissen, E. Hoorn, R. Mathijssen, 2022, British Journal of Cancer.

Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands

W. Jarnagin, N. Kemeny, A. Cercek, 2019, Annals of Surgical Oncology.

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

M. D. de Jonge, H. Arkenau, J. D. de Bono, 2015, Clinical Cancer Research.

Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide

A. Sparreboom, P. de Bruijn, G. Du, 2017, Clinical and translational science.

Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients

R. Mathijssen, A. van der Gaast, F. D. de Man, 2019, Cancers.

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours

J. Verweij, I. Judson, S. Kaye, 2004, British Journal of Cancer.

Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma

T. Visser, R. Peeters, R. Mathijssen, 2017, The Journal of clinical endocrinology and metabolism.

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours.

J. Verweij, C. Lamers, M. D. de Jonge, 2009, European Journal of Cancer.

The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients

R. Mathijssen, C. van Kesteren, S. Bins, 2021, Pharmaceuticals.

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

J. Bloem, J. Verweij, J. Nortier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

J. Verweij, U. Banerji, M. Garrett, 2012, Clinical Cancer Research.

Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.

R. Mathijssen, R. V. van Schaik, S. Bins, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Phase I, safety, pharmacokinetic and biomarker study of BAY 57-9352, an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors.

J. Verweij, H. Gelderblom, D. Voliotis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel

A. Jager, R. Mathijssen, P. de Bruijn, 2021, Cancers.

I. B. Borel Rinkes, C. Punt, M. D'Angelica, 2019, BMC Cancer.

A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.

M. D. de Jonge, T. Busman, A. Krivoshik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib-induced blood pressure rise does not involve aldosterone: observations in a patient after bilateral adrenalectomy.

J. Versmissen, R. Mathijssen, A. Danser, 2018, Journal of hypertension.

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1

R. Mathijssen, R. V. van Schaik, S. Bins, 2023, Clinical Pharmacokinetics.

A phase Ib, open-label, dose-escalation study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors.

M. Cotreau, E. D. de Vries, J. Gietema, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma

R. Mathijssen, P. de Bruijn, T. van Gelder, 2021, Pharmaceuticals.

The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study.

P. de Bruijn, R. V. van Leeuwen, K. Hussaarts, 2024, Clinical pharmacokinetics.

Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.

T. Visser, R. Peeters, R. Mathijssen, 2011, Thyroid : official journal of the American Thyroid Association.